--------------------------------------------------------------------------------
Legacy Novozymes is delivering solid growth and earnings in a year characterized
by changing market demands, with 6% organic sales growth in Q4 and 5% organic
sales growth in 2023. This marks the last financial reporting from legacy
Novozymes, and the new company, Novonesis, is already a reality.
COPENHAGEN, Denmark - February 1, 2024. In the 2023 financial year, legacy
Novozymes delivers 5% organic sales growth - 6% organic sales growth in the
fourth quarter alone - an EBIT-margin before special items((*)) of 25.4%, and
ROIC including goodwill before special items* of 16.5%. As Novozymes just closed
the combination with Chr. Hansen on January 29, and the annual report now is
expected to be released on February 8, this announcement only contains selected
unaudited numbers. Full audited financial statements as well as non-financial
numbers will be released with the annual report on February 8. Novonesis will
present a 2024 financial outlook no later than March 31.
"Legacy Novozymes has leveraged its strengths of a well-diversified portfolio,
unique production capabilities, and broad market presence to deliver strong
growth in a volatile market. Biosolutions hold the key to some of the world's
biggest challenges, and the growth in 2023 confirms the continued trajectory to
growth as well as demand and strong momentum, says Ester Baiget, President &
CEO, and continues:
"Now, we start a new chapter as Novonesis. The combination between two great
companies is now a reality, and we are set to further accelerate growth and to
develop transformative biosolutions as the leading global biosolutions partner.
We have gathered the brightest minds, and together with my more than 10,000
colleagues, we will unlock the limitless potential of biosolutions. A special
thank you to all our stakeholders for your support. We are ready to lead the new
era of biosolutions."
In the 2023 financial year, legacy Novozymes launched 18 new biosolutions to
meet customer needs, seven of which were public.
Growth rates across business areas
For the full year, organic performance by business area was 5% in Household
Care, -2% in Food, Beverages & Human Health, 23% in Bioenergy, -6% in Grain &
Tech Processing, and 3% in Agriculture, Animal Health & Nutrition.
Performance in Food, Beverages & Human Health was impacted by destocking and a
tough year-on-year comparator. Grain & Tech Processing was affected by an
expected reduction in sales to Covid-19 test kits and declining textile market
demand.
Strong growth across both developed and emerging markets
Legacy Novozymes sales grew 5% in 2023 organically compared to the previous year
with 6% growth in developed markets and 4% growth emerging markets.
Bioenergy was the main driver of growth in developed markets with contributions
from Agriculture, Animal Health & Nutrition and Household Care despite declining
industry volumes.
Growth in emerging markets was driven by Bioenergy and with contributions from
Household Care.
For 2023, organic growth rates by geography were 3% in Europe, Middle East &
Africa, 7% in North America,
-1% in Asia Pacific, and 17% in Latin America.

  Media Relations
  Lina Danstrup
  Head of External Communications
  Phone: +45 30 77 05 52
  anse@novozymes.com (mailto:anse@novozymes.com)
  Investor Relations
  Tobias Cornelius Björklund
  Head of Investor Relations
  Phone: +45 30 77 86 82
  tobb@novozymes.com (mailto:tobb@novozymes.com)

((*)) Special items include costs related to the combination with Chr. Hansen
Â